- Home
- LGND vs RARE Comparison
LGND vs RARE Comparison
Compare LGND & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | RARE |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 1992 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LGND | RARE |
|---|---|---|
| Price | $193.83 | $33.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $144.71 | $85.20 |
| AVG Volume (30 Days) | 139.7K | ★ 1.4M |
| Earning Date | 08-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $181,488,000.00 | ★ $630,598,000.00 |
| Revenue This Year | $18.41 | $19.09 |
| Revenue Next Year | $18.87 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.40 | 20.63 |
| 52 Week Low | $81.74 | $25.81 |
| 52 Week High | $129.90 | $46.75 |
Technical Indicators
Market Signals| Indicator | LGND | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 41.60 |
| Support Level | $188.69 | $35.65 |
| Resistance Level | $192.44 | $36.81 |
| Average True Range (ATR) | 6.59 | 1.49 |
| MACD | -0.28 | -0.23 |
| Stochastic Oscillator | 56.16 | 0.21 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.